CHIL's Tax Bill Halved by ₹86.66 Cr After IT Dept Correction

INSURANCE
Whalesbook Corporate News Logo
AuthorAarav Shah|Published at:
CHIL's Tax Bill Halved by ₹86.66 Cr After IT Dept Correction
Overview

Religare Enterprises' subsidiary, Care Health Insurance (CHIL), received a tax department order correcting a technical error. This cuts CHIL's tax bill for Assessment Year 2022-23 by ₹86.66 Crores to ₹86.66 Crores. The reduction benefits Religare's overall financials, though a separate appeal for AY 2022-23 is still pending.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

CHIL's Tax Bill Halved by ₹86.66 Cr After IT Dept Correction

Care Health Insurance Limited (CHIL), a subsidiary of Religare Enterprises, had its tax demand for Assessment Year 2022-23 cut by ₹86.66 Crores. The Income-Tax Department issued a rectification order correcting a technical error, lowering CHIL's tax liability from ₹173.32 Crores to ₹86.66 Crores.

IT Department Issues Rectification Order

Religare Enterprises disclosed that its subsidiary, Care Health Insurance Limited (CHIL), received a Rectification Order from the Income-Tax Department on April 28, 2026. The order corrects a technical issue in the tax demand for Assessment Year (AY) 2022-23. This means CHIL's net tax liability for AY 2022-23 is now ₹86.66 Crores, a reduction of ₹86.66 Crores from the earlier ₹173.32 Crores. CHIL and Religare Enterprises were informed of this order on April 29, 2026. The original tax demand was first disclosed on September 28, 2024.

Financial Impact

Lowering CHIL's immediate tax obligations offers a direct financial benefit. Because CHIL's financial results are included in Religare Enterprises' consolidated statements, this reduced tax liability helps the group's overall profitability and financial health.

Previous Tax Matters and Current Appeal

Care Health Insurance is a significant health insurer in India and a key part of Religare Enterprises. CHIL has faced previous tax notices. In March 2025, it received a demand for ₹104.77 Crores for Assessment Years 2020-21 and 2021-22. In March 2026, CHIL received income tax assessment orders totaling ₹140.20 Crores for AY 2023-24 and 2024-25, which the company plans to contest. Crucially, CHIL still has a pending appeal concerning other additions made in the Assessment Year 2022-23 order, separate from the technical error that was just rectified.

Key Changes

  • CHIL's tax payments for AY 2022-23 are now halved.
  • Religare Enterprises' consolidated profit figures will show a positive adjustment.
  • This lower tax obligation helps with the company's financial planning and cash flow.

Remaining Risk

The main risk continues to be the outcome of CHIL's pending appeal against other additions within the Assessment Year 2022-23 order. This appeal is currently with the relevant authority.

Market Context

CHIL is a major standalone health insurer in India, facing competition from companies like HDFC Ergo, Star Health, Niva Bupa, and ICICI Lombard. Tax demands and regulatory scrutiny are not uncommon in the sector, with many companies facing increased compliance expectations.

Looking Ahead

Investors will watch the outcome of CHIL's pending appeal on other additions for Assessment Year 2022-23. Updates from the Income-Tax Department or CHIL on other tax matters will also be monitored. Religare Enterprises' consolidated financial reports will reflect this tax adjustment. CHIL's operational performance and premium growth in the competitive health insurance market remain key focus areas.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.